MRC1 and rectal cancer: MMR IHC interpretation is usually straightforward, but challenges can be occasionally encountered, including tumor staining weaker than control, cytoplasmic staining, post-neoadjuvant therapy (treated rectal cancer may show decreased or absent MMR protein expression), missense mutation with retained protein antigenicity.